<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
    <channel>
        <title><![CDATA[Sweden Herald - Per Hansen]]></title>
        <description><![CDATA[The latest Sweden Herald stories about Per Hansen, in English.]]></description>
        <link>https://swedenherald.com/people/per-hansen</link>
        <generator>RSS for Node and Next.js</generator>
        <lastBuildDate>Tue, 10 Nov 2026 14:05:01 GMT</lastBuildDate>
        <atom:link href="https://swedenherald.com/rss/people/per-hansen.xml" rel="self" type="application/rss+xml"/>
        <copyright><![CDATA[Sweden Herald]]></copyright>
        <language><![CDATA[en-US]]></language>
        <ttl>60</ttl>
        <item>
            <title><![CDATA[Billion-dollar decline expected in Novo Nordisk profits]]></title>
            <description><![CDATA[Danish pharmaceutical company Novo Nordisk's results are affecting the entire nation's economy. The quarterly report will be released tomorrow - and profits are expected to fall by billions. Novo Nordisk has lost some momentum, says Per Hansen, savings economist at Nordnet in Denmark.]]></description>
            <link>https://swedenherald.com/article/billiondollar-decline-expected-in-novo-nordisk-profits</link>
            <guid isPermaLink="true">https://swedenherald.com/article/billiondollar-decline-expected-in-novo-nordisk-profits</guid>
            <category><![CDATA[Business News]]></category>
            <dc:creator><![CDATA[Sweden Herald]]></dc:creator>
            <pubDate>Tue, 05 May 2026 07:55:41 GMT</pubDate>
            <enclosure url="https://static.swedenherald.com/a63c7c28-d34e-4db7-9507-da5cd835d575/a63c7c28-d34e-4db7-9507-da5cd835d575.jpg" length="0" type="image/jpeg"/>
            <media:content url="https://static.swedenherald.com/a63c7c28-d34e-4db7-9507-da5cd835d575/a63c7c28-d34e-4db7-9507-da5cd835d575.jpg" medium="image" type="image/jpeg" width="1200" height="675"/>
        </item>
        <item>
            <title><![CDATA[Patent expires - Ozempic price may be pressured]]></title>
            <description><![CDATA[After a turbulent year, new challenges await pharmaceutical giant Novo Nordisk. Competitors are poised to capitalize as the patent on its best-selling drug expires in several markets.]]></description>
            <link>https://swedenherald.com/article/patent-expires-ozempic-price-may-be-pressured</link>
            <guid isPermaLink="true">https://swedenherald.com/article/patent-expires-ozempic-price-may-be-pressured</guid>
            <category><![CDATA[Business News]]></category>
            <dc:creator><![CDATA[Sweden Herald]]></dc:creator>
            <pubDate>Sun, 15 Feb 2026 07:35:18 GMT</pubDate>
            <enclosure url="https://static.swedenherald.com/2d81e6bc-d7d9-44c4-89dc-0001871fc567/2d81e6bc-d7d9-44c4-89dc-0001871fc567.jpg" length="0" type="image/jpeg"/>
            <media:content url="https://static.swedenherald.com/2d81e6bc-d7d9-44c4-89dc-0001871fc567/2d81e6bc-d7d9-44c4-89dc-0001871fc567.jpg" medium="image" type="image/jpeg" width="1200" height="675"/>
        </item>
        <item>
            <title><![CDATA[Novo Nordisk exceeds expectations: "Outstanding"]]></title>
            <description><![CDATA[The Danish pharmaceutical giant Novo Nordisk, known for the weight loss preparations Ozempic and Wegovy, reports a full-year sales figure that beats market expectations. It's a really good ending to a turbulent year, says Per Hansen, investment economist at Nordnet in Denmark.]]></description>
            <link>https://swedenherald.com/article/novo-nordisk-exceeds-expectations</link>
            <guid isPermaLink="true">https://swedenherald.com/article/novo-nordisk-exceeds-expectations</guid>
            <category><![CDATA[Business News]]></category>
            <dc:creator><![CDATA[Sweden Herald]]></dc:creator>
            <pubDate>Wed, 05 Feb 2025 06:50:37 GMT</pubDate>
            <enclosure url="https://static.swedenherald.com/e68c182a-6100-472c-bf30-b46b12408e00/e68c182a-6100-472c-bf30-b46b12408e00.jpg" length="0" type="image/jpeg"/>
            <media:content url="https://static.swedenherald.com/e68c182a-6100-472c-bf30-b46b12408e00/e68c182a-6100-472c-bf30-b46b12408e00.jpg" medium="image" type="image/jpeg" width="1600" height="1026"/>
        </item>
        <item>
            <title><![CDATA[The Shock in Denmark: "Completely Crazy"]]></title>
            <description><![CDATA[The crash in the Novo Nordisk share is "completely crazy", believes Per Hansen, investment economist at Nordnet in Denmark. It has a huge significance for investors, but also for the Danish economy as a whole, he says.]]></description>
            <link>https://swedenherald.com/article/the-shock-in-denmark-completely-crazy</link>
            <guid isPermaLink="true">https://swedenherald.com/article/the-shock-in-denmark-completely-crazy</guid>
            <category><![CDATA[Business News]]></category>
            <dc:creator><![CDATA[Sweden Herald]]></dc:creator>
            <pubDate>Fri, 20 Dec 2024 13:58:27 GMT</pubDate>
            <enclosure url="https://static.swedenherald.com/027567c3-42f4-4b41-95d8-2189d86af791/027567c3-42f4-4b41-95d8-2189d86af791.jpg" length="0" type="image/jpeg"/>
            <media:content url="https://static.swedenherald.com/027567c3-42f4-4b41-95d8-2189d86af791/027567c3-42f4-4b41-95d8-2189d86af791.jpg" medium="image" type="image/jpeg" width="1600" height="962"/>
        </item>
    </channel>
</rss>